目的　评价89SrCl2 对肺癌骨转移性疼痛镇痛效果及不良反应。方法　对 57例确诊为肺癌骨转移的病人分成二组进行临床对比研究 ,1 4例应用89SrCl2 (89Sr组 )和 43例用1 53Sm EDTMP(1 53Sm组 )。结果　89SrCl2 和1 53Sm EDTMP对骨痛止痛有效率分别为 78 6%和79 1 % ,二组比较差异无显著性 ,但前者的疗效维持时间明显长于后者 ,且安全、适合家庭治疗。结论　对经济条件好 ,不便到医院治疗的肺癌多发骨转移患者可首选89SrCl2 治疗 Objective To evaluate the analgesic effect and adverse reactions of 89SrCl2 on bone metastatic pain in patients with lung cancer. Methods Fifty-seven patients with bone metastases diagnosed as lung cancer were divided into two groups: 89 cases (89Sr group) and 43 cases (153 cases). Results The effective rates of 89SrCl2 and 153Sm EDTMP on pain and pain were 78.6% and 79.1%, respectively. There was no significant difference between the two groups. However, the former maintained a significantly longer effective duration than the latter and was safe and suitable for family therapy. Conclusion 89SrCl2 is the first choice for patients with multiple bone metastases of lung cancer who are in good financial condition and inconvenient to go to the hospital for treatment